Expression of inhibitor proteins that control primordial follicle reserve decreases in cryopreserved ovaries after autotransplantation

Journal of Assisted Reproduction and Genetics
Soner CelikCiler Celik-Ozenci

Abstract

Even with 86 live births reported globally so far, the mechanism of primordial follicle loss following autotransplantation of the frozen-thawed ovarian tissue needs further evaluation. Pten, Tsc1, p27, and Amh are the inhibitor proteins that play crucial roles in suppressing the transition from the primordial follicle to primary state, maintaining the primordial follicle reserve. In this study, we aimed to evaluate whether the expression patterns of these proteins change and it may be related to the global primordial follicle loss after autotransplantation of the frozen-thawed ovarian tissue. Four groups were established in rats: fresh-control, frozen/thawed, fresh-transplanted, and frozen/thawed and transplanted. After slow freezing and thawing process, two ovarian pieces were transplanted into the back muscle of the same rat. After 2 weeks, grafts were harvested, fixed, and embedded into the paraffin block. Normal and atretic primordial/growing follicle count was performed in all groups. Ovarian tissues were evaluated for the dynamic expressions of the Pten, Tsc1, p27, and Amh proteins using immunohistochemistry, and H-score analyses were done. Ovarian tissue cryopreservation does not change the expression patterns of inhibit...Continue Reading

References

Mar 10, 1999·Journal of Reproduction and Fertility·D NugentR G Gosden
Sep 25, 1999·Science·A Di CristofanoP P Pandolfi
Jun 1, 2002·Science·Lewis C Cantley
Nov 6, 2002·Reproduction : the Official Journal of the Society for the Study of Fertility·Alexandra L L DurlingerAxel P N Themmen
Sep 25, 2004·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Tomer IsraelyMichal Neeman
Mar 8, 2006·The Journal of Surgical Research·Fernando López-Neblina, Luis H Toledo-Pereyra
May 3, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephanie J LeeUNKNOWN American Society of Clinical Oncology
Sep 29, 2006·The New England Journal of Medicine·Peter B CrinoElizabeth Petri Henske
Jan 27, 2007·Cell·Philipp Kaldis
Nov 14, 2007·Journal of Assisted Reproduction and Genetics·Maki GotoFumitaka Kikkawa
Jan 17, 2008·Genes & Development·Maurice Phillip DeYoungLeif W Ellisen
Jul 8, 2008·Developmental Biology·George B JohnDiego H Castrillon
Aug 12, 2008·Fertility and Sterility·Anne-Sophie Van EyckJacques Donnez
May 29, 2009·Human Reproduction Update·I DemeestereY Englert
Jun 23, 2009·Fertility and Sterility·Anne-Sophie Van EyckMarie-Madeleine Dolmans
Jul 11, 2009·Endocrine Reviews·Deepak Adhikari, Kui Liu
Oct 13, 2010·Human Reproduction·Ozgur Oktem, Bulent Urman
Dec 30, 2011·Molecular Human Reproduction·S J Silber
Mar 22, 2014·Reproduction, Fertility, and Development·Ferda Topal-CelikkanEsra Atabenli-Erdemli
Jul 27, 2015·Journal of Assisted Reproduction and Genetics·Jacques Donnez, Marie-Madeleine Dolmans
Mar 30, 2016·Current Opinion in Obstetrics & Gynecology·Kazuhiro KawamuraAaron J W Hsueh
Apr 21, 2016·Cancer Cell International·Takashi KohnohYoshinori Hasegawa
Aug 3, 2016·International Journal of Molecular Sciences·Sheng-Hsiang LiRobert Kuo-Kuang Lee
Mar 9, 2017·Proceedings of the National Academy of Sciences of the United States of America·Kara N GoldmanRobert J Schneider
Nov 4, 2017·Journal of Assisted Reproduction and Genetics·Zohar GavishDror Meirow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.